SC
TGTX icon

Steven Cohen’s TG Therapeutics TGTX Stock Holding History

Steven Cohen’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.26M Buy
+95,800
New +$3.92M 0.01% 1719

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Steven Cohen's TGTX Position: Q2 2026 in Review

Steven Cohen opened a new position in TG Therapeutics (TGTX) in Q2 2026: 264,963 shares worth $14.6M. The stake represents 0.02% of the portfolio and ranks #1059 among its holdings. This is a return to the name: Steven Cohen previously reported a position in TGTX as recently as Q4 2025.

Steven Cohen first reported a position in TGTX in Q1 2018 and has held it in 13 quarters since. The position peaked at $25.8M in Q2 2025. 426 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Steven Cohen held 264,963 shares of TG Therapeutics worth $14.6M as of Q2 2026.
  • TG Therapeutics was a new Steven Cohen position in Q2 2026.
  • TG Therapeutics made up 0.02% of Steven Cohen's portfolio in Q2 2026, its #1059 holding.
  • Steven Cohen first reported a position in TG Therapeutics in Q1 2018 and has held it in 13 quarters since.
  • Steven Cohen's TG Therapeutics position peaked at $25.8M in Q2 2025.
  • 426 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.